Rabeprazole Coadministration Controls Ulcer Recurrence in Patients on Low-dose Aspirin Therapy: A Multicenter Prospective Study

OBJECTIVE: To evaluate the efficacy and safety of rabeprazole coadministration with low-dose aspirin (LDA). METHODS: From 2015 to 2018, we conducted a large-scale, multicenter, prospective observational study to assess the safety and efficacy of treatment with rabeprazole (5 or 10 mg/day) in combina...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Yoshikazu, Kato, Mototsugu, Sugizaki, Katsuya, Ikeuchi, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017235/
https://www.ncbi.nlm.nih.gov/pubmed/35908971
http://dx.doi.org/10.2169/internalmedicine.9646-22
Descripción
Sumario:OBJECTIVE: To evaluate the efficacy and safety of rabeprazole coadministration with low-dose aspirin (LDA). METHODS: From 2015 to 2018, we conducted a large-scale, multicenter, prospective observational study to assess the safety and efficacy of treatment with rabeprazole (5 or 10 mg/day) in combination with LDA. RESULTS: The incidence of adverse reactions was 0.73% (11/1,513 patients), with no serious adverse reactions. We found no trend toward increases in the incidence of adverse reactions with increases in treatment duration. The cumulative recurrence rate of ulcers by Week 52 (Kaplan-Meier estimates) was 3.50% (range, 1.56-7.75%). No gastrointestinal bleeding was reported. CONCLUSION: Rabeprazole in combination with LDA appears as safe and effective in real-world situations as in clinical trials.

Ejemplares similares